Skip to content

Total debt at other companies

Cytokinetics logo
CytokineticsCYTK
$418.21M+75.8%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$395.09M+0.1%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$2.68M-13.3%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$168.68M+623%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$137K-87.8%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$3.96B+61.3%
Enterprise value$3.93B+63.5%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $3.79M.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s total debt?
Edgewise Therapeutics, Inc. (EWTX) reported total debt of $3.79M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s total debt changed year-over-year?
Edgewise Therapeutics, Inc.'s total debt decreased by 16.8% year-over-year, from $4.56M to $3.79M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s total debt?
Over 3 years (2022 to 2025), Edgewise Therapeutics, Inc.'s total debt has grown at a -3.3% compound annual growth rate (CAGR), from $4.41M to $3.99M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.